Building the Evidence Generation Roadmap:
The Role of Real World Data in Drug Development
About this webinar
Despite the increasing demand for Real World Evidence (RWE) generation across a product’s lifecycle, there are challenges that need to be carefully addressed. These include the choice of the appropriate data sources and methodological approaches to structure and analyze such data to produce viable action plans.
During the webinar, learn how to effectively address these challenges. Using actual case studies, viewers will understand the development of an effective strategy that incorporates epidemiology, health economics and outcome research, and uses already available Real World data. When such data are not available, learn how to develop the data to support an effective evidence generation plan.
Who should attend
- Health Economic Outcomes Research (HEOR)
- Comparative Effectiveness/Research
- Clinical Data
- Bioinformatics/Analytics
- Epidemiology
- Pharmacoeconomics
- Pharmacovigilance
Featured Speakers
Alex Exuzides, PhD
Alex has over 21 years of experience in the application of advanced statistical methods in medicine, health services, health economics, comparative effectiveness research, epidemiology, program evaluation, and risk assessment. His experience includes projects with complex and novel methodological approaches in retrospective database analyses, observational studies, efficacy and safety studies, patient-reported outcomes, pharmacoeconomic, and epidemiological research. Prior to ICON, he was Director of Clinical Outcomes for a leading disease management company, where he was the primary liaison to research partnerships, providing analytical evaluation of new products and program performance focused on diabetes, cardiovascular disease, asthma/COPD, nephrology, and oncology. He is based in San Francisco, with frequent tenures to NYC.
Partner for this event
ICON
ICON’s Commercialisation & Outcomes practices provide insights to clients on strategies and execution for long-term value through customised engagements that fit the compound, the company and the market, maximising products’ success and their benefits to patients’ health.
Related webinars
More from Icon.
Strategic approaches for early clinical trials in neurodegenerative diseases
Insights into first-in-human study design of oligonucleotides
When patients lead: Breaking barriers in ultra-rare disease drug development
ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Becoming a sponsor of choice for high-performing sites
Riding the data wave: How pharma can navigate disruptions in open claims
Beyond the bench: The advantages of GMP over USP compounding in early phase development
Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases
Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies
Introducing ICON Strategic Solutions FSP Services: How This Model Supports Sponsors in Korea
From Fragmented to Fluid: A Deep Dive into Claims Data Innovation
Get ready for a new wave of clinical trials in Schizophrenia: how Sites and Sponsors can avoid conceptual mistakes